drugset / Trial / NCT06478667
The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity
RandomizedParallel-groupSingle-blindSupportive care
Summary
To evaluate the potential role of levosimendan as an inotropic agent in aluminum phosphide-induced cardiotoxicity
Timeline
- Start
- 2024-12-20
- Primary completion
- 2025-01-20
- Completion
- 2025-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levosimendan | Other / unclassified | 0.05 ug/kg | — |
| Comparator | Levosimendan | Other / unclassified | 0.2 ug/kg | — |